TP53 and pancreatic adenocarcinoma: Given that ADGRG6 is a G protein-coupled receptor (GPCR) situated on the cell membrane, identifying specific inhibitors targeting this receptor could emerge as a powerful strategy for curbing the progression of PAAD driven by mutated p53.